A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

Conclusions RO6839921 showed reduced pharmacokinetic exposure variability and a safety profile comparable with that of  oral idasanutlin. Although this study indicated that RO6839921 could be administered to patients, the results did not provide sufficient differentiation or improvement in the biologic or safety profile compared with oral idasanutlin to support continued development.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research